国产精品亚洲LV粉色,在电梯伦流澡到高潮H男男,久久久亚洲一区二区三区,国色天香A区与B区

掃碼關注公眾號           掃碼咨詢技術支持           掃碼咨詢技術服務
  
客服熱線:400-901-9800  客服QQ:4009019800  技術答疑  技術支持  質量反饋  關于我們  聯系我們
男女猛烈xx00免费视频试看,日本PEEJAPANTV小便,乖宝撞的你舒不舒服H
首頁 > 產品中心 > 一抗 > 產品信息
Anti-PD-1 & PD-L1 Reference Antibody (Reozalimab Biosimilar) (BIO1018SM)  
訂購熱線:400-901-9800
訂購郵箱:sales@m.hhi8.com
訂購QQ:  400-901-9800
技術支持:techsupport@m.hhi8.com
100ug/詢價
1mg/詢價
5mg/詢價
大包裝/詢價

產品編號 BIO1018SM
英文名稱 Anti-PD-1 & PD-L1 Reference Antibody (Reozalimab Biosimilar)
別    名 Angiopoietin 2 & VEGF; Reozalimab  
抗體來源
克隆類型 Monoclonal
交叉反應 Human
產品應用
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
理論分子量 143.84kDa
性    狀 Lyophilized
亞    型 IgG-like
純化方法 Protein A
緩 沖 液 100 mM Pro-Ac 20mM Arg pH 5.0
保存條件 -80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions;Avoid repeated freeze-thaw cycles.
注意事項 This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
PubMed PubMed
產品介紹
產品圖片
Co-incubation of Reozalimab with PD-1-NF-AT-Jurkat and CD3L-huPD-L1-CHO-K cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Reozalimab was able to block the PD-1/PD-L1 signaling pathway, and the EC50 was 0.728 nM.
Reozalimab bound to huPD-L1-CHO-K cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Reozalimab bound to huPD-L1-CHO-K cells, and the EC50 was 2.237 nM.
Reozalimab bound to huPD-1-Jurkat cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Reozalimab bound to huPD-1-Jurkat cells, and the EC50 was 0.990 nM.
Reozalimab bound to PD-L1 protein, and then rebounded to secondary antibodies(Anti-human-κ+λ-HRP) , and read OD450. As shown in fig, Reozalimab bound to huPD-L1-Fc, and the EC50 was 0.015 nM.
Reozalimab bound to PD-1 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Reozalimab bound to huPD-1-His, and the EC50 was 0.004 nM.
The purity of Anti-PD-1 & PD-L1 Reference Antibody (Reozalimab) is 95.07%, determined by SEC-HPLC.
Anti-PD-1 & PD-L1 Reference Antibody (Reozalimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The detected weight of Anti-PD-1 & PD-L1 Reference Antibody (Reozalimab) is 143.56 kDa.
版權所有 2004-2026 www.m.hhi8.com 北京博奧森生物技術有限公司
通過國際質量管理體系ISO 9001:2015 GB/T 19001-2016    證書編號: 00124Q34771R2M/1100
通過國際醫療器械-質量管理體系ISO 13485:2016 GB/T 42061-2022    證書編號: CQC24QY10047R0M/1100
京ICP備05066980號-1         京公網安備110107000727號